ArticleOncogene2020
ΔNp63α exerts antitumor functions in cervical squamous cell carcinoma.
Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Dual functions of the ΔNp63-miR-141-3p-YAP1 regulatory axis in cervical cancer progression are dependent on histological subtype.Scientific reports · 2025Article
- Review
- Tight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies.Pharmaceuticals (Basel, Switzerland) · 2024Article
- TP63-TRIM29 axis regulates enhancer methylation and chromosomal instability in prostate cancer.Epigenetics & chromatin · 2024Article
- ∆Np63α inhibits Rac1 activation and cancer cell invasion through suppression of PREX1.Cell death discovery · 2024Article
- Circular RNA ARHGAP5 inhibits cisplatin resistance in cervical squamous cell carcinoma by interacting with AUF1.Cancer science · 2023Article
- A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.Frontiers in immunology · 2023Article
- Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications.Frontiers in oncology · 2023Review
- The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia.Blood advances · 2022Article
- SYT7 acts as an oncogene and a potential therapeutic target and was regulated by ΔNp63α in HNSCC.Cancer cell international · 2021Article
- lncRNA PART1 and MIR17HG as ΔNp63α direct targets regulate tumor progression of cervical squamous cell carcinoma.Cancer science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular basis underlying the aggressive nature and excessive proliferation of cervical squamous cancer cell remains unclear. ΔNp63α is the predominant isotype of p63 expressed in the epithelia and regulates epithelial cell differentiation. The pro-/anti-tumor role of ΔNp63α in different kinds of solid tumors remains controversial and the precise molecular mechanisms are still elusive. In this study, we uncovered the molecular functions of ΔNp63α in cervical squamous cell carcinoma to clarify its roles as a tumor suppressor. We demonstrated that ΔNp63α suppressed cell migration, invasiveness, and tumor growth in SiHa and ME-180 cells with both in vivo and in vitro assays. Mechanistic investigation via RNA-sequencing and chromatin immunoprecipitation-sequencing revealed that ΔNp63α exerted its antitumor capacity via regulating the expression of a cohort of cell junction genes. Further, we showed that ZNF385B and CLDN1 were two direct ΔNp63α targets with significant relevance to cervical squamous cell carcinoma examined in cell cultures, tumor xenografts, and clinic tumors. We also demonstrated that ΔNp63α downregulated NFATC1 to reduce cisplatin resistance. These findings shed new lights on functions of ΔNp63α in tumors and providing novel insights in targeted therapy of cervical cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.